ArriVent BioPharma (AVBP) Income towards Parent Company (2023 - 2026)
ArriVent BioPharma (AVBP) reported Income towards Parent Company of -$83.4 million for Q1 2026, up 11.22% on a YoY basis from -$75.0 million in Q1 2025, and down 133.45% sequentially from -$35.7 million in Q4 2025.
ArriVent BioPharma (AVBP) Income towards Parent Company (2023 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 4 years of Income towards Parent Company data on file, last reported at -$83.4 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company rose 11.22% year-over-year to -$83.4 million; the trailing twelve-month figure through Mar 2026 stood at -$251.0 million (down 7.6% YoY), and the FY2025 full-year result was -$198.0 million, down 51.32% from the prior year.
- Income towards Parent Company slipped to -$83.4 million in Q1 2026, from -$35.7 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$12.2 million in Q1 2023 to a low of -$93.9 million in Q1 2025.
- A 4-year average of -$49.8 million and a median of -$55.0 million in 2024 frame the typical range for Income towards Parent Company.
- Peak annual rise in Income towards Parent Company reached 68.04% in 2024, while the deepest fall reached 340.46% in 2024.
- Tracing AVBP's Income towards Parent Company over 4 years: stood at -$65.3 million in 2023, then surged by 68.04% to -$20.9 million in 2024, then slumped by 71.1% to -$35.7 million in 2025, then tumbled by 133.45% to -$83.4 million in 2026.
- Business Quant data shows AVBP's Income towards Parent Company at -$83.4 million in Q1 2026, -$35.7 million in Q4 2025, and -$63.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | ArriVent BioPharma | 1.37 Bn | 1.37 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83.37 Mn |
| Dec 31, 2025 | -35.71 Mn |
| Sep 30, 2025 | -63.45 Mn |
| Jun 30, 2025 | -68.42 Mn |
| Mar 31, 2025 | -93.91 Mn |
| Dec 31, 2024 | -20.87 Mn |
| Sep 30, 2024 | -63.43 Mn |
| Jun 30, 2024 | -55.00 Mn |
| Mar 31, 2024 | -50.38 Mn |
| Dec 31, 2023 | -65.32 Mn |
| Sep 30, 2023 | -14.40 Mn |
| Jun 30, 2023 | -21.57 Mn |
| Mar 31, 2023 | -12.17 Mn |